Clinical Trial: Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730138) titled 'Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer' on July 01.

Brief Summary: A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer

Study Start Date: Oct. 15, 2026

Study Type: INTERVENTIONAL

Condition: Gastric Ulcer

Intervention: DRUG: DWP14012 40mg (Fexuprazan)

DWP14012 40mg(Fexuprazan) + placebo of Lansoprazole

DRUG: Lansoprazole 30mg

Lansoprazole 30mg + Placebo of DWP14012 40mg

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Daewoong Pharmaceutical Co...